Rifampin may improve diabetic foot osteomyelitis outcomes, but its extensive drug–drug interactions could hamper its use. Here, through a review of the medications prescribed to a cohort of 190 persons with diabetic foot osteomyelitis, we show that rifabutin, a rifamycin with fewer drug–drug interactions, would be easier to implement in practice.